The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC
Michel Ducreux, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, explores the emerging synergistic mechanisms of anti-androgenic agents and immune checkpoints inhibitors in hepatocellular carcinoma (HCC), in particular with reference to the combination of intravenous atezolizumab and bevacizumab, which has shown impressive responses in the first-line setting. Continuing on from this success, Prof. Ducreux highlights the attempts being made to further understand how this treatment compares with the current standard of care, sorafenib, in a Phase III trial and eagerly anticipates the results to emerge by the end of the year (IMbrave150; NCT03434379). This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
